DurAVR™

THE FIRST-IN-CLASS BIOMIMETIC TAVR VALVE SHAPED FOR NATIVE PERFORMANCE
The first-in-class Biomimetic TAVR valve shaped for native performance

ANNUAL GENERAL MEETING, 29 MAY 2023

Watch the live presentation given by CEO Wayne Paterson, at this year's Annual General Meeting hosted by Anteris on the 29 May 2023. 

LEARN MORE

EUROPCR 2023 PHYSICIAN PANEL  

Watch this physician panel and hear Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss early safety and feasibility of the first-in-class biomimetic transcatheter aortic valve – DurAVR™ THV.

LIVE PHYSICIAN INTERVIEW AT AGM

CEO Wayne Paterson and Dr. Karl Poon discuss his experience with DurAVR™ at Anteris Technologies’ Annual General Meeting.

LEARN MORE

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.

LEARN MORE
Anteris Technologies Heart Valve DurAVR

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.

LEARN MORE
Anteris Technologies Heart Valve DurAVR

INSPIRED BY PATIENTS. EMPOWERED BY PURPOSE.

Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.

INVEST IN ANTERIS (ASX: AVR)

We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Investors
Anteris Technologies Invest AVR ASX

INVEST IN ANTERIS (ASX: AVR)

We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Investors
Anteris Technologies Invest AVR ASX

LATEST ANTERIS NEWS

LATEST ANTERIS NEWS

EUROPCR 2023 DurAVR™ DATA RELEASE

EuroPCR 2023 DurAVR™ THV First-In-Human 1-Year Data Presentation

VIEW DATA
Anteris Technologies Receives Utility Patent for Novel Transcatheter Heart Valve Replacement Technology

EUROPCR 2023 PHYSICIAN PANEL

EuroPCR discussion featuring Drs Christopher Meduri, Susheel Kodali & João Cavalcante

WATCH HERE
EuroPCR discussion featuring Drs Christopher Meduri, Susheel Kodali & João Cavalcante

ANNUAL GENERAL MEETING

 

 

 

VIEW PRESENTATION
FDA Grants Anteris Expanded Approval for Anteris